Coagulation Analyzer Market Size, Share, Growth by 2030

The coagulation analyzers market is projected to expand from US$ 4,183.71 million in 2022 to US$ 6,690.08 million by 2030, reflecting a compound annual growth rate (CAGR) of 6.0% during the period from 2022 to 2030.

This report outlines the prevailing trends and the factors propelling market growth. The surge in the market is primarily due to the rising incidence of blood disorders and the increasing prevalence of cardiovascular diseases. Furthermore, the emergence of point-of-care (POC) coagulation analyzers is anticipated to be a significant trend throughout the forecast period. Nevertheless, the high costs and stringent regulations associated with coagulation analyzers may impede market growth from 2022 to 2030.

Cardiovascular diseases (CVDs) are responsible for millions of fatalities globally each year. Key contributors to CVDs include hypertension, obesity, and diabetes. According to the 2022 Heart Disease & Stroke Statistical Update Fact Sheet from the Global Burden of Disease, around 119.1 million individuals succumbed to CVDs in 2020. The report also indicated that the global prevalence of stroke and ischemic stroke in 2020 was 89.1 million and 68.2 million, respectively. The National Center for Chronic Disease Prevention and Health Promotion reported that approximately 697,000 individuals died from heart diseases in the United States, equating to 1 in every 5 deaths. The American Heart Association predicts that over 130 million Americans, or 45.1%, will develop some form of CVD by 2035. In Europe, CVDs are a leading cause of mortality, accounting for 45% of deaths in the region and 37% in the European Union annually. High blood pressure is a significant risk factor for CVDs in low- and middle-income countries, contributing to over 75% of death cases. The Global Burden of Disease Study 2019 identified CVDs as the leading cause of death in the Asia Pacific region, resulting in 10.8 million fatalities or 35% of total deaths.

Moreover, the American College of Cardiology reports that approximately 1.2 million angioplasties are performed annually. There is also a notable increase in coronary artery bypass grafting (CABG) procedures due to the rising prevalence of coronary artery disease, myocardial infarctions, sedentary lifestyles, and hypertension. Globally, around 400,000 CABG surgeries are conducted each year, with about 200,000 performed in the US, according to research published in NLM in 2022. Coagulation tests play a crucial role in preventing blood clots that could lead to heart attacks. Coagulation analyzers are utilized during CABG and angioplasty to monitor blood clotting status. Consequently, the growing incidence of cardiovascular diseases is a key driver for the expansion of the coagulation analyzer market.

Increasing Organic and Inorganic Strategies by Key Players

In recent years, shifts in lifestyle and an aging population have led to a rise in various blood disorders, increasing the demand for early diagnosis and treatment. To improve the quality of life for individuals suffering from hemorrhagic diseases, key players are implementing various organic and inorganic strategies.

- In 2019, Nihon Kohden announced plans to establish a hematology analyzer reagent factory in Dubai.

- In October 2021, Trivitron Healthcare launched a new range of coagulation analyzer products manufactured by Diagon Ltd in India.

- In June 2021, Trivitron Healthcare introduced the NANO H5 and NANO H110, which monitor diabetes, thalassemia, and hemoglobin variations.

- In February 2021, Siemens Healthineers and Sysmex Corporation renewed their long-standing agreement for the global supply, distribution, sales, and service of hemostasis products, extending their collaboration for multiple years. Siemens Healthineers will distribute Sysmex's automated blood coagulation analyzers, including the CN-3000 and CN-6000, as part of this agreement, providing laboratories with next-generation fully automated coagulation testing solutions.

- In July 2020, Sysmex Corporation launched the Automated Blood Coagulation Analyzers CN-6500/CN-3500 in Japan, which measure blood coagulation and platelet aggregation parameters, as well as thrombosis and hemostasis parameters.

- In February 2018, Horiba, a Japanese manufacturer of precision instruments, launched the Yumizen G, a range of semi-automatic to fully automatic hemostasis solutions for clinical testing.

- In May 2018, Beckman Coulter introduced the DxH 900 hematology analyzer, designed to perform complete blood counts and differential white blood cell tests with minimal repeats for mid-to-high-volume clinical laboratories.

These initiatives by key market players are expected to create additional opportunities for the growth of the coagulation analyzer market during the forecast period.

The coagulation analyzers market is categorized based on product type, test, technology, and end user. The clinical laboratory analyzers segment is further divided into systems and consumables, with the clinical laboratory analyzers segment holding the largest market share in 2022. Conversely, point-of-care testing analyzers are projected to exhibit significant CAGR in the coagulation analyzers market. The market is segmented by test type into prothrombin time testing, fibrinogen testing, D-dimer testing, platelet function testing, activated clotting time testing, activated partial thromboplastin time testing, and others, with prothrombin time testing accounting for the largest market share in 2022. The D-dimer testing segment is expected to experience the highest CAGR during the forecast period. By technology, the market is divided into optical technology, mechanical technology, electrochemical technology, and others, with optical technology holding the largest market share in 2022. In terms of application, the market is segmented into clinical laboratories, hospitals, and others, with clinical laboratories holding the highest market share in 2022 and expected to register the highest CAGR during the forecast period.

Companies in the coagulation analyzers market are employing various organic and inorganic strategies, including product launches and approvals, as well as acquisitions, collaborations, and partnerships. These strategies enable market players to expand their operations and enhance their geographic presence, contributing to overall market growth. Additionally, acquisition and partnership strategies help strengthen customer bases and broaden product portfolios. Significant developments by key players in the coagulation analyzers market are noted below.

The report on the coagulation analyzers market references major primary and secondary sources, including the National Center for Biotechnology Information, Global Burden of Disease, and the National Library of Medicine.